Cardiogenic Shock Market
Cardiogenic Shock Market Analysis by Treatment Type (Cardiogenic Shock Treatment Drugs, Antiplatelet medication, Mechanical Circulatory Support (MCS) devices, Invasive Ventilation (endotracheal tube), In Vitro Test Kits), by End User, by Region - Global Market Insights 2022 to 2032
Analysis of Cardiogenic Shock market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cardiogenic Shock Market Outlook (2022 to 2032)
The global cardiogenic shock market was valued at US$ 3.29 Billion in 2021 and is expected to reach US$ 6.32 Billion by 2032, expanding at a CAGR of 6.2% over the 2022 to 2032 time frame.
The drugs segment, under treatment type, dominated the global cardiogenic shock market in 2021 in terms of revenue and market share, accounting for 52.7% of the total market, and is expected to surge ahead at a CAGR of 7.8% over the forecast period (2022 to 2032).
| Report Attributes | Details |
|---|---|
| Cardiogenic Shock Market Size (2021) | US$ 3.29 Billion |
| Estimated Market Value (2022) | US$ 3.45 Billion |
| Forecasted Market Value (2032) | US$ 6.32 Billion |
| Global Market Growth Rate (2022 to 2032) | 6.2% CAGR |
| East Asia Market Share (2021) | 12.2% |
| East Asia Market Growth Rate (2022 to 2032) | 7.7% CAGR |
| China Market Growth Rate (2022 to 2032) | 8.4% CAGR |
| Share of Top 5 Countries | 55% |
| Key Market Players | ABIOMED; Bayer AG Abbott; Viatris; Par Pharmaceutical; Getinge Group; Terumo Corporation; Medtronic, AstraZeneca; F. Hoffman-La Roche Ltd; Others |
Cardiogenic shock treatment accounts for nearly 6.4% share of the global cardiovascular device market, which was estimated to be around US$ 51.9 Billion in 2021.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Cardiogenic Shock Treatment Demand Analysis (2017 to 2021) Compared to Market Outlook (2022 to 2032)
The global cardiogenic shock treatment devices and drugs market expanded at a CAGR of 4.1% over the last five years.
Cardiogenic shock is a situation where the heart fails to pump blood and oxygen to the cease organs and can be a reason for cease-organ failure. Cardiogenic shock results from a coronary heart attack and is life-threatening.
Signs of cardiogenic shock include chest pain, dizziness, fainting, shortness of breath, profuse sweating, nausea, and vomiting. Other reasons for cardiogenic shock include myocarditis or infection of the coronary heart muscles, endocarditis or contamination of the coronary heart valves, drug overdose, and a sedentary lifestyle.
According to the JACC: Heart Failure research paper, November 2020, cardiogenic shock is said to adversely affect acute myocardial infarction, as with the increasing population, patients have been clinically in a complex state. In 2022, CDC stated that, nearly 805,000 people in the U.S. suffer from heart attacks yearly.
Rising burden of cardiovascular diseases and growing incidence of cardiogenic shock (epidemiology), increasing ageing population, and growing economic burden are likely to stimulate the growth of the cardiogenic shock market.
Considering this, Fact.MR expects the worldwide cardiogenic shock market to expand at a CAGR of 6.2% over the forecast period (2022 to 2032).
What’s Mainly Driving Demand for Cardiogenic Shock Treatment Drugs & Devices?
“High Prevalence of Cardiovascular Disease and Advancements in Related Devices”
Cardiogenic shock management necessitates a collaborative effort involving organizational methodologies, accurate diagnosis using equipment such as electrocardiogram, echocardiogram, coronary angiography etc., and therapeutic management to preserve blood flow.
Collaborative techniques entail interpersonal contact among team members and healthcare experts to develop a strategy protocol for the start and management of high-risk situations, as well as patient safety precautions. These cardiogenic shock treatments aid in improving patient outcomes and lengthening survival times.
Furthermore, the shock team, which entails interventional cardiology, critical care medicine, anesthesiology, cardiothoracic surgery, perfusion services, nursing, and rehabilitation, is quite beneficial. Use of interdisciplinary action has had a favourable influence on patient care.
Despite the high rate of cardiovascular disease mortality and substantially lower R&D spending, cardiovascular care has shown improvements in patient management.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What’s Restraining Growth of Cardiogenic Shock Market Players?
“High Cost Associated with Treatment and Mechanical-assisted Devices”
For illnesses such as coronary heart disease, cardiomyopathy, and congenital heart disease, a heart transplant is done, in which, a diseased heart is replaced with a healthy donor’s heart.
With the rise in cardiovascular disorders, including systolic dysfunction, valvular dysfunction, diastolic dysfunction, cardiac arrhythmias, coronary artery disease and other mechanical complications, the need for heart transplants has increased.
According to the American Transplant Foundation, the number of deceased donors in the United States increased 6% from 11,870 in 2019 to 12,588 in 2020.
A heart transplant is the gold standard treatment; however, the number of donors for heart transplants appears to be decreasing with the number of recipients increasing.
The expense of treating related diseases remains high due to the high death rate of cardiovascular diseases. If cardiogenic shock is not recognized correctly, it can progress to significant multi-organ failure.
Despite the ease with which physicians can deliver mechanical circulatory devices for treatment, the expense of the standard of care might be a stumbling block to the expansion of the cardiogenic shock treatment market.
Country-wise Insights
What is the U.S. Market Stance for Cardiogenic Shock Treatment?
The U.S. accounted for over 88% of the North America cardiogenic shock market in 2021, owing to the development of many treatment facilities and rising investments in the healthcare sector.
Moreover, approvals by the U.S. FDA are increasing and resulting in more products getting launched, making the U.S a high revenue-generating country.
- For instance, in February 2021, Abbott’s CardioMEMS™ HF system received FDA approval to support patients battling earlier-stage heart failure.
Also, rise in awareness about cardiac disorders offers lucrative opportunities for the U.S. market for cardiogenic shock treatment.
Will Germany Be a Lucrative Market for Cardiogenic Shock?
Germany accounted for 22.9% market share in the Europe cardiogenic shock market in 2021.
As the geriatric population is increasing, Germany is focusing on various research & development programs and supporting different startups, which is boosting the cardiogenic shock market in the country.
- For instance, in November 2020, Bayer initiated support for five new startup companies as part of the company’s G4A Digital Health Partnerships Program.
The focus is to foster the development of a digital health ecosystem while driving forward integrated healthcare solutions in the fields of cardiometabolic and renal diseases, oncology, and women’s health.
What are the Factors Fueling Demand for Cardiogenic Shock Solutions in China?
China accounted for 43.4% of the East Asia cardiogenic shock market in 2021.
The provision of major manufacturing services to meet clinical needs and high production of raw materials for drug manufacturing are some of the key trends driving market expansion in China. This is ultimately strengthening its position in the East Asia market.
Cost-effective production of devices generates a high revenue share for China in the region’s cardiogenic shock treatment market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Why is Demand for Cardiogenic Shock Drugs Gaining Traction?
By treatment type, drugs held the highest market share of 52.7% in 2021, with the segment expected to expand at 7.8% CAGR over the forecast period. This is being influenced by increasing research & development on cardiogenic shock treatment.
Furthermore, as drugs are considered the first line of treatment and are cost-effective, they are preferable in comparison to other treatment options, which makes this segment the most lucrative for the forecast period.
Competitive Landscape
Key manufacturers of cardiogenic shock treatment products are actively focusing on the expansion of their portfolios by introducing new products that are technologically advanced, as a strategy to maintain their position in the global cardiogenic shock market
- In August 2021, the U.S. FDA approved the expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin.
Similarly, recent developments related to companies operating in the cardiogenic shock market have been tracked by the team at Fact.MR, which are available in the full report.
Key Segments Covered in Cardiogenic Shock Industry Research
-
By Treatment Type :
- Treatment Drugs
- Inotropic Agents
- Thrombolytic
- Vasopressors
- Norepinephrine
- Epinephrine
- Vasopressin
- Phenylephrine
- Dobutamine
- Antiplatelet medication
- Other blood-thinning medications
- Cardiogenic Shock Treatment Devices
- Mechanical Circulatory Support (MCS) devices
- Intravascular Micro axial LVAD
- Intra-Aortic Balloon Pump (IABP)
- Axial Flow Pumps
- Extracorporeal Membrane Oxygenation (ECMO)
- Artery Bypass Pumps
- Invasive Ventilation (endotracheal tube)
- In Vitro Test Kits
- N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP)
- Troponin
- Treatment Drugs
-
By End User :
- Hospitals
- Ambulatory Surgical centers
- Cardiac Catheterization Labs
- Office-Based Clinics
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Key Inclusions
- 6. Market Background
- 7. Global Market Demand Value (US$ Mn) Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Treatment Type
- 8.1. Drugs
- 8.1.1. Inotropic Agents
- 8.1.2. Thrombolytic
- 8.1.3. Vasopressors
- 8.1.3.1. Norepinephrine
- 8.1.3.2. Epinephrine
- 8.1.3.3. Vasopressin
- 8.1.3.4. Phenylephrine
- 8.1.3.5. Dobutamine
- 8.1.4. Antiplatelet medication
- 8.1.5. Other blood-thinning medications
- 8.2. Devices
- 8.2.1. Mechanical Circulatory Support (MCS) devices
- 8.2.1.1. Intravascular Micro axial LVAD
- 8.2.1.2. Intra-Aortic Balloon Pump (IABP)
- 8.2.1.3. Axial Flow Pumps
- 8.2.1.4. Extracorporeal Membrane Oxygenation (ECMO)
- 8.2.1.5. Artery Bypass Pumps
- 8.2.2. Invasive Ventilation (endotracheal tube)
- 8.2.1. Mechanical Circulatory Support (MCS) devices
- 8.3. In vitro test kits
- 8.3.1. N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP)
- 8.3.2. Troponin I
- 8.1. Drugs
- 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by End User
- 9.1. Hospitals
- 9.2. Ambulatory Surgical Centers
- 9.3. Cardiac Catheterization Labs
- 9.4. Office Based Clinics
- 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. East Asia
- 10.5. South Asia
- 10.6. Oceania
- 10.7. Middle East and Africa (MEA)
- 11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 14. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 15. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 16. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 17. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 18. Key & Emerging Countries Market Analysis and Forecast 2022 & 2032
- 19. Market Structure Analysis
- 20. Competition Deep Dive
- 20.1. ABBOTT Diagnostics
- 20.2. Angiodynamics, Inc.
- 20.3. Boston Scientific Corporation
- 20.4. Edwards Life Science Corporation
- 20.5. Cook Medical
- 20.6. Medtronic Inc.
- 20.7. Terumo Medical Corporation
- 20.8. bioMerieux Inc.
- 20.9. Roche Diagnostics
- 20.10. Beckman Coulter (Danaher Corporation)
- 20.11. SIEMENS AG
- 20.12. GE Healthcare
- 20.13. Nihon Kohden
- 20.14. Philips Healthcare
- 20.15. Mindray Bio-Medical Electronics Co., Ltd.
- 20.16. Drägerwerk AG & Co. KGaA
- 20.17. Mylan Pharmaceuticals
- 20.18. Alembic Pharmaceuticals Ltd
- 20.19. Alkem Laboratories Ltd
- 20.20. Cadila Pharmaceuticals Ltd
- 20.21. Sanofi S.A.
- 20.22. Sun Pharmaceutical Industries Ltd
- 20.23. Teva Pharmaceutical Industries
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 02: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 03: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 04: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 05: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
Table 06: North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 07: North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 08: North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 9: North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 10: North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 11: Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 12: Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 13: Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 14: Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 15: Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 16: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 17: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 18: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 19: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 20: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 21: South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 22: South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 23: South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 24: South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 25: South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 26: East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 27: East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 28: East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 29: East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 30: East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 31: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 32: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 33: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 34: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 35: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 36: MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 37: MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 38: MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
Table 39: MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
Table 40: MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis, 2017 to 2021
Figure 02: Global Market Value (US$ Mn) Forecast, 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity, 2022 to 2032
Figure 04: Global Market Value Share (%) Analysis 2022 & 2032, By Treatment Type
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, By Treatment Type
Figure 06: Global Market Attractiveness Analysis, By Treatment Type
Figure 07: Global Market Value Share (%) Analysis 2022 & 2032, By End User
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, By End User
Figure 09: Global Market Attractiveness Analysis, By End User
Figure 10: Global Market Value Share (%) Analysis 2022 & 2032, By Region
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, By Region
Figure 12: Global Market Attractiveness Analysis, By Region
Figure 13: North America Market Value Share By Treatment Type 2022 (E)
Figure 14: North America Market Value Share By End User 2022 (E)
Figure 15: North America Market Value Share By Country 2022 (E)
Figure 16: North America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 17: North America Market Value Forecast (US$ Mn), 2022 to 2032
Figure 18: North America Market Attractiveness Analysis By Treatment Type , 2022to 2032
Figure 19: North America Market Attractiveness Analysis by End User, 2022 to 2032
Figure 20: North America Market Attractiveness Analysis, By Country 2022 to 2032
Figure 21: Latin America Market Value Share By Treatment Type 2022 (E)
Figure 22: Latin America Market Value Share By End User 2022 (E)
Figure 23: Latin America Market Value Share By Country 2022 (E)
Figure 24: Latin America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 25: Latin America Market Value Forecast (US$ Mn), 2022 to 2032
Figure 26: Latin America Market Attractiveness Analysis By Treatment Type , 2022 to 2032
Figure 27: Latin America Market Attractiveness Analysis by End User, 2022 to 2032
Figure 28: Latin America Market Attractiveness Analysis, By Country 2022 to 2032
Figure 29: Europe Market Value Share By Treatment Type 2022 (E)
Figure 30: Europe Market Value Share By End User 2022 (E)
Figure 31: Europe Market Value Share By Country 2022 (E)
Figure 32: Europe Market Value Analysis (US$ Mn), 2017 to 2021
Figure 33: Europe Market Value Forecast (US$ Mn), 2022 to 2032
Figure 34: Europe Market Attractiveness Analysis By Treatment Type , 2022 to 2032
Figure 35: Europe Market Attractiveness Analysis by End User, 2022 to 2032
Figure 36: Europe Market Attractiveness Analysis, By Country 2022 to 2032
Figure 37: South Asia Market Value Share By Treatment Type 2022 (E)
Figure 38: South Asia Market Value Share By End User 2022 (E)
Figure 39: South Asia Market Value Share By Country 2022 (E)
Figure 40: South Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 41: South Asia Market Value Forecast (US$ Mn), 2022 to 2032
Figure 42: South Asia Market Attractiveness Analysis By Treatment Type , 2022to 2032
Figure 43: South Asia Market Attractiveness Analysis by End User, 2022 to 2032
Figure 44: South Asia Market Attractiveness Analysis, By Country 2022 to 2032
Figure 45: East Asia Market Value Share By Treatment Type 2022 (E)
Figure 46: East Asia Market Value Share By End User 2022 (E)
Figure 47: East Asia Market Value Share By Country 2022 (E)
Figure 48: East Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 49: East Asia Market Value Forecast (US$ Mn), 2022 to 2032
Figure 50: East Asia Market Attractiveness Analysis By Treatment Type , 2022to 2032
Figure 51: East Asia Market Attractiveness Analysis by End User, 2022 to 2032
Figure 52: East Asia Market Attractiveness Analysis, By Country 2022 to 2032
Figure 53: Oceania Market Value Share By Treatment Type 2022 (E)
Figure 54: Oceania Market Value Share By End User 2022 (E)
Figure 55: Oceania Market Value Share By Country 2022 (E)
Figure 56: Oceania Market Value Analysis (US$ Mn), 2017 to 2021
Figure 57: Oceania Market Value Forecast (US$ Mn), 2022 to 2032
Figure 58: Oceania Market Attractiveness Analysis By Treatment Type , 2022to 2032
Figure 59: Oceania Market Attractiveness Analysis by End User, 2022 to 2032
Figure 60: Oceania Market Attractiveness Analysis, By Country 2022 to 2032
Figure 61: MEA Market Value Share By Treatment Type 2022 (E)
Figure 62: MEA Market Value Share By End User 2022 (E)
Figure 63: MEA Market Value Share By Country 2022 (E)
Figure 64: MEA Market Value Analysis (US$ Mn), 2017 to 2021
Figure 65: MEA Market Value Forecast (US$ Mn), 2022 to 2032
Figure 66: MEA Market Attractiveness Analysis By Treatment Type , 2022to 2032
Figure 67: MEA Market Attractiveness Analysis by End User, 2022 to 2032
Figure 68: MEA Market Attractiveness Analysis, By Country 2022 to 2032
Figure 69: U.S Market Value Proportion Analysis, 2021
Figure 70: Global Vs. U.S Growth Comparison
Figure 71: U.S. Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 72: U.S. Market Share Analysis (%) by End User, 2022 & 2032
Figure 73: Canada Market Value Proportion Analysis, 2021
Figure 74: Global Vs. Canada Growth Comparison
Figure 75: Canada Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 76: Canada Market Share Analysis (%) by End User, 2022 & 2032
Figure 77: Brazil Market Value Proportion Analysis, 2021
Figure 78: Global Vs. Brazil Growth Comparison
Figure 79: Brazil Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 80: Brazil Market Share Analysis (%) by End User, 2022 & 2032
Figure 81: Mexico Market Value Proportion Analysis, 2021
Figure 82: Global Vs. Mexico Growth Comparison
Figure 83: Mexico Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 84: Mexico Market Share Analysis (%) by End User, 2022 & 2032
Figure 85: Argentina Market Value Proportion Analysis, 2021
Figure 86: Global Vs. Argentina Growth Comparison
Figure 87: Argentina Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 88: Argentina Market Share Analysis (%) by End User, 2022 & 2032
Figure 89: U.K. Market Value Proportion Analysis, 2021
Figure 90: Global Vs. U.K. Growth Comparison
Figure 91: U.K Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 92: U.K Market Share Analysis (%) by End User, 2022 & 2032
Figure 93: Germany Market Value Proportion Analysis, 2021
Figure 94: Global Vs. Germany Growth Comparison
Figure 95: Germany Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 96: Germany Market Share Analysis (%) by End User, 2022 & 2032
Figure 97: France Market Value Proportion Analysis, 2021
Figure 98: Global Vs. France Growth Comparison
Figure 99: France Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 100: France Market Share Analysis (%) by End User, 2022 & 2032
Figure 101: Italy Market Value Proportion Analysis, 2021
Figure 102: Global Vs. Italy Growth Comparison
Figure 103: Italy Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 104: Italy Market Share Analysis (%) by End User, 2022 & 2032
Figure 105: Spain Market Value Proportion Analysis, 2021
Figure 106: Global Vs. Spain Growth Comparison
Figure 107: Spain Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 108: Spain Market Share Analysis (%) by End User, 2022 & 2032
Figure 109: Russia Market Value Proportion Analysis, 2021
Figure 110: Global Vs. Russia Growth Comparison
Figure 111: Russia Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 112: Russia Market Share Analysis (%) by End User, 2022 & 2032
Figure 113: BENELUX Market Value Proportion Analysis, 2021
Figure 114: Global Vs. Poland Growth Comparison
Figure 115: BENELUX Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 116: BENELUX Market Share Analysis (%) by End User, 2022 & 2032
Figure 117: India Market Value Proportion Analysis, 2021
Figure 118: Global Vs. India Growth Comparison
Figure 119: India Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 120: India Market Share Analysis (%) by End User, 2022 & 2032
Figure 121: Thailand Market Value Proportion Analysis, 2021
Figure 122: Global Vs. Thailand Growth Comparison
Figure 123: Thailand Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 124: Thailand Market Share Analysis (%) by End User, 2022 & 2032
Figure 125: Indonesia Market Value Proportion Analysis, 2021
Figure 126: Global Vs. Indonesia Growth Comparison
Figure 127: Indonesia Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 128: Indonesia Market Share Analysis (%) by End User, 2022 & 2032
Figure 129: Malaysia Market Value Proportion Analysis, 2022
Figure 130: Global Vs. Malaysia Growth Comparison
Figure 131: Malaysia Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 132: Malaysia Market Share Analysis (%) by End User, 2022 & 2032
Figure 133: China Market Value Proportion Analysis, 2021
Figure 134: Global Vs. China Growth Comparison
Figure 135: China Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 136: China Market Share Analysis (%) by End User, 2022 & 2032
Figure 137: South Korea Market Value Proportion Analysis, 2021
Figure 138: Global Vs. South Korea Growth Comparison
Figure 139: South Korea Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 140: South Korea Market Share Analysis (%) by End User, 2022 & 2032
Figure 141: Japan Market Value Proportion Analysis, 2021
Figure 142: Global Vs. Japan Growth Comparison
Figure 143: Japan Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 144: Japan Market Share Analysis (%) by End User, 2022 & 2032
Figure 145: Australia Market Value Proportion Analysis, 2021
Figure 146: Global Vs. Australia Growth Comparison
Figure 147: Australia Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 148: Australia Market Share Analysis (%) by End User, 2022 & 2032
Figure 149: New Zealand Market Value Proportion Analysis, 2021
Figure 150: Global Vs. New Zealand Growth Comparison
Figure 151: France Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 152: New Zealand Market Share Analysis (%) by End User, 2022 & 2032
Figure 153: GCC Countries Market Value Proportion Analysis, 2021
Figure 154: Global Vs. GCC Countries Growth Comparison
Figure 155: GCC Countries Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 156: GCC Countries Market Share Analysis (%) by End User, 2022 & 2032
Figure 157: South Africa Market Value Proportion Analysis, 2021
Figure 158: Global Vs. South Africa Growth Comparison
Figure 159: South Africa Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 160: South Africa Market Share Analysis (%) by End User Type, 2022 & 2032
Figure 161: Turkey Market Value Proportion Analysis, 2021
Figure 162: Global Vs. South Africa Growth Comparison
Figure 163: Turkey Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 164: Turkey Market Share Analysis (%) by End User, 2022 & 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the demand outlook for cardiogenic shock treatment?
The global market for cardiogenic shock is expected to reach US$ 6.32 Billion by the end of 2032.
What are the top 5 countries driving demand for cardiogenic shock treatment?
The U.S., Germany, U.K., China, and France are driving most growth of the cardiogenic shock market.
What is the market outlook for the U.S.?
The U.S. accounted for 88.2% share of the North American market share in 2021.
At what percentage is demand for cardiogenic shock treatment expected to register growth in Europe?
The Europe market is predicted to expand at 5.2% CAGR over the forecast period.
Who are the leading companies manufacturing cardiogenic shock devices and drugs?
Top companies in this market are ABIOMED, Bayer AG, Abbott, Viatris, Par Pharmaceutical, Getinge Group, Terumo Corporation, Medtronic, AstraZeneca, and F. Hoffman-La Roche Ltd.
How is the market faring in South Korea and Japan?
The South Korea cardiogenic shock market is expected to exhibit 5.2% CAGR, with the Japanese market growing even faster at 7.8% CAGR.
How much is the cardiogenic shock market valued at?
The global cardiogenic shock market was worth US$ 3.29 Bn in 2021.
At what CAGR did the market expand over the past 5 years?
Revenue from the cardiogenic shock market increased at a CAGR of 4.1% from 2017 to 2021.
Cardiogenic Shock Market